---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-120345"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:05:55.125719+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atara Q1 net income $38M; FDA lifts EBVALLO holds; $16M offering closes May 16

## Summary
- Net income of $38.0M ($3.50 diluted EPS) vs net loss of $31.8M in Q1 2024; revenue $98.1M, up from $27.4M, driven by Pierre Fabre milestone.
- Cash $13.8M at Mar 31, 2025; with $16M gross proceeds from May offering, expects runway into Q1 2026.
- FDA lifted clinical holds on EBVALLO; Type A meeting Q2 2025 to address CRL; plans to resume Phase 3 ALLELE study.
- Workforce reduced ~30% in May, retaining ~23 staff; FY2025 operating expenses expected to decrease ~65% YoY.
- James Huang (Panacea) and Nachi Subramanian (Redmile) appointed to board effective after offering close.

## SEC filing metadata
- accession: 0001193125-25-120345
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-120345
- JSON: https://secwatch.observer/filing/0001193125-25-120345.json
- Plain text: https://secwatch.observer/filing/0001193125-25-120345.txt

## Key facts
- Executive change
  James Huang was appointed as Director at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm
- Executive change
  Nachi Subramanian was appointed as Director at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.